UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway

Frontiers in immunology, 2021-09, Vol.12, p.712572-712572

2021

Volltextzugriff (PDF)

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2021-03, Vol.384 (11), p.1028-1037

2021

Volltextzugriff (PDF)

Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients

British journal of haematology, 2018-10, Vol.183 (1), p.136-139

2018

Volltextzugriff (PDF)

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Blood, 2022-09, Vol.140 (9), p.980-991

2022

Volltextzugriff (PDF)

Autoimmune Hemolytic Anemia

The Medical clinics of North America, 2017-03, Vol.101 (2), p.351-359

2017

Volltextzugriff (PDF)

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

Haematologica (Roma), 2022-07, Vol.107 (7), p.1698-1702

2022

Volltextzugriff (PDF)

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

The New England journal of medicine, 2015-09, Vol.373 (11), p.1032-1039

2015

Volltextzugriff (PDF)

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition

Blood reviews, 2023-05, Vol.59, p.101041-101041, Article 101041

2023

Volltextzugriff (PDF)

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study

Annals of hematology, 2022-10, Vol.101 (10), p.2169-2177

2022

Volltextzugriff (PDF)

Thrombosis in patients with paroxysmal nocturnal hemoglobinuria

Seminars in thrombosis and hemostasis, 2011-04, Vol.37 (3), p.315-321

Weitz, Ilene C

2011

Volltextzugriff (PDF)

Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy

Obstetrics and gynecology (New York. 1953), 2020-03, Vol.135 (3), p.723-727

2020

Volltextzugriff (PDF)

Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab

Transfusion (Philadelphia, Pa.), 2015-10, Vol.55 (10), p.2398-2403

2015

Volltextzugriff (PDF)

Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study

Annals of hematology, 2024-05, Vol.103 (5), p.1803-1803

2024

Volltextzugriff (PDF)

Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease

American journal of hematology, 2023-08, Vol.98 (8), p.1246-1253

2023

Volltextzugriff (PDF)

Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center

Platelets (Edinburgh), 2019-04, Vol.30 (3), p.413-417

2019

Volltextzugriff (PDF)

A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Acta haematologica, 2020-06, Vol.143 (3), p.244-249

2020

Volltextzugriff (PDF)

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

The Lancet. Haematology, 2022-09, Vol.9 (9), p.e648-e659

2022

Volltextzugriff (PDF)

Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study

European journal of haematology, 2023-03, Vol.110 (3), p.280-288

2023

Volltextzugriff (PDF)

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Haematologica (Roma), 2021-01, Vol.106 (1), p.230-237

2021

Volltextzugriff (PDF)

Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab

Hematology (Luxembourg), 2020-01, Vol.25 (1), p.327-334

2020

Volltextzugriff (PDF)

Complement-mediated thrombotic microangiopathy associated with lupus nephritis

Blood advances, 2018-08, Vol.2 (16), p.2090-2094

2018

Volltextzugriff (PDF)

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

Thrombosis research, 2012-09, Vol.130 (3), p.361-368

2012

Volltextzugriff (PDF)

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

Hematology, 2024-12, Vol.29 (1)

2024

Volltextzugriff (PDF)

Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment

Orphan drugs, 2015-01, Vol.5, p.75

Weitz, Ilene Ceil

2015

Volltextzugriff (PDF)

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis

Thrombosis research, 2010-04, Vol.125, p.S106-S107

Weitz, Ilene C

2010

Volltextzugriff (PDF)

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(107)

Publikationsform

Sprache

Englisch
(122)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Humans
(40)
Hematology
(36)
Female
(22)
Adult
(20)
Middle Aged
(17)
Male
(16)
Aged
(14)
Hemolysis
(14)
Paroxysmal Nocturnal Hemoglobinuria
(14)
Thrombosis
(13)
Biological And Medical Sciences
(11)
Medical Sciences
(11)
Anemia
(9)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(9)
Cardiovascular System & Cardiology
(8)
General & Internal Medicine
(8)
Hemoglobin
(8)
Hemoglobinuria, Paroxysmal - Drug Therapy
(8)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria

Effective treatment of chemotherapy induced atypical Haemolytic Uraemic Syndrome: a case series of 7 treated patients

Sutimlimab in patients with cold agglutinin disease: results of the randomized placebo-controlled phase 3 CADENZA trial

Autoimmune Hemolytic Anemia

Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition

Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study

Thrombosis in patients with paroxysmal nocturnal hemoglobinuria

Multidrug Therapy for Refractory Immune Thrombocytopenia in Pregnancy

Life‐threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab

Correction to: Sutimlimab improves quality of life in patients with cold agglutinin disease: results of patient-reported outcomes from the CARDINAL study

Sustained inhibition of complement C1s with sutimlimab over 2 years in patients with cold agglutinin disease

Ethnic and racial difference in Helicobacter pylori infection in patients with immune thrombocytopenia treated at a major urban medical center

A Retrospective Study of the Combination of Rituximab, Cyclophosphamide and Dexamethasone for the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial

Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study

Characterization of breakthrough hemolysis events observed in the phase 3 randomized studies of ravulizumab versus eculizumab in adults with paroxysmal nocturnal hemoglobinuria

Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab

Complement-mediated thrombotic microangiopathy associated with lupus nephritis

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria: new concepts in pathophysiology and treatment

Thrombosis in Paroxysmal Nocturnal Hemoglobinuria – insights into the role of complement in thrombosis

Suchergebnisse filtern